Edition:
United States

Almirall SA (ALM.MC)

ALM.MC on Madrid SE C.A.T.S.

8.95EUR
22 Sep 2017
Change (% chg)

€-0.21 (-2.29%)
Prev Close
€9.16
Open
€9.15
Day's High
€9.19
Day's Low
€8.89
Volume
433,628
Avg. Vol
565,334
52-wk High
€16.88
52-wk Low
€7.85

Latest Key Developments (Source: Significant Developments)

Almirall announces phase III positive Duaklir results for COPD
Thursday, 7 Sep 2017 03:36am EDT 

Sept 7 (Reuters) - ALMIRALL SA ::SAYS PHASE III STUDY SHOWS DUAKLIR SIGNIFICANTLY IMPROVES LUNG FUNCTION IN MODERATE TO VERY SEVERE STABLE COPD.TO GET SALES-RELATED MILESTONES FROM ASTRAZENECA ASSOCIATED TO DUAKLIR SALES IN US, ACCORDING TO GLOBAL COLLABORATION BETWEEN BOTH COMPANIES.  Full Article

Almirall board approves appointment of Peter Guenter as new CEO
Monday, 28 Aug 2017 12:29pm EDT 

Aug 28 (Reuters) - Almirall SA ::BOARD APPROVES APPOINTMENT OF PETER GUENTER AS CEO EFFECTIVE OCT. 1 FOLLOWING SUCCESSION PLAN INITIATED MORE THAN A YEAR AGO.  Full Article

Almirall appoints Ron Menezes as President and General Manager of Aqua Pharmaceuticals
Tuesday, 22 Aug 2017 02:48am EDT 

Aug 22 (Reuters) - ALMIRALL SA ::NAMES RON MENEZES AS PRESIDENT AND GENERAL MANAGER OF AQUA PHARMACEUTICALS.  Full Article

Almirall H1 EBITDA down 52.6 pct at 58.6 mln euros YoY
Monday, 24 Jul 2017 01:52am EDT 

July 24 (Reuters) - ALMIRALL SA ::H1 EBITDA DOWN 52.6 PERCENT AT 58.6 MILLION EUROS VERSUS YEAR AGO.SEES UPCOMING LAUNCH OF SKILARENCE IN EUROPE IN Q3.H1 GROSS MARGIN IMPACTED BY REDUCTION IN SALES IN HIGHER MARGIN GEOGRAPHIES.  Full Article

Almirall H1 net result turns to loss of 73.1 mln euros
Monday, 24 Jul 2017 01:37am EDT 

July 24 (Reuters) - ALMIRALL SA ::H1 NET LOSS 73.1 MILLION EUROS VERSUS PROFIT 80.5 MILLION EUROS YEAR AGO.H1 NET SALES 328.5 MILLION EUROS VERSUS 388.3 MILLION EUROS YEAR AGO.  Full Article

Almirall says EC approves its Skilarence drug for chronic plaque psoriasis
Tuesday, 27 Jun 2017 01:59am EDT 

June 27 (Reuters) - ALMIRALL SA :EUROPEAN COMMISSION (EC) APPROVES ALMIRALL'S SKILARENCE FOR MODERATE-TO-SEVERE CHRONIC PLAQUE PSORIASIS.DUE TO START MARKETING SKILARENCE IN THIRD QUARTER OF 2017 IN ALL EU MEMBER STATES, ALSO IN ICELAND AND NORWAY.  Full Article

Almirall is ready with authorized generic of Acticlate to be introduced to US market‍​
Monday, 19 Jun 2017 02:11am EDT 

June 19 (Reuters) - ALMIRALL SA ::SAYS IT IS READY WITH AN AUTHORIZED GENERIC (AG) OF ACTICLATE TO BE INTRODUCED TO THE US MARKET‍​.TO COMMERCIALISE A NEW, MARKET EXCLUSIVE LINE EXTENSION FOR ACTICLATE ACNE TREATMENT PRODUCT.  Full Article

Almirall and Leo Pharma to collaborate on minimally invasive skin sampling method
Tuesday, 30 May 2017 04:05am EDT 

May 30 (Reuters) - ALMIRALL SA ::ALMIRALL AND LEO PHARMA TO COLLABORATE ON DEVELOPING AND CLINICALLY VALIDATING MINIMALLY INVASIVE SKIN SAMPLING METHOD.  Full Article

Almirall Q1 net profit down at 19.6 mln euros
Monday, 8 May 2017 02:00am EDT 

May 8 (Reuters) - ALMIRALL SA ::Q1 EBITDA 55.0 MILLION EUROS ($60.4 MILLION) VERSUS 54.8 MILLION EUROS YEAR AGO.Q1 NET PROFIT 19.6 MILLION EUROS VERSUS 21.7 MILLION EUROS YEAR AGO.Q1 REVENUE UP 5 PERCENT AT 210.7 MILLION EUROS VERSUS 201.0 MILLION EUROS YEAR AGO.Q1 RESEARCH AND DEVELOPMENT EXPENSES UP 26 PERCENT AT 24.2 MILLION EUROS VERSUS 19.2 MILLION EUROS YEAR AGO.SEES ITS SKILARENCE DRUG FOR PSORIASIS TO REACH PEAK SALES OF OVER 50 MILLION EUROS.SEES TO START SELLING SKILARENCE IN EUROPE IN Q3 2017.SEES TO LAUNCH TILDRAKIZUMAB IN 2018 WITH PEAK SALES OF OVER 200 MILLION EUROS.CONFIRMS FY 2017 EBITDA AND REVENUE GUIDANCE.  Full Article

Almirall gets positive CHMP opinion for drug to treat psoriasis
Friday, 21 Apr 2017 06:42am EDT 

April 21 (Reuters) - Almirall SA ::Receives positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for dimethyl fumarate for the treatment of patients with moderate-to-severe chronic plaque psoriasis.  Full Article

BRIEF-Almirall announces phase III positive Duaklir results for COPD

* SAYS PHASE III STUDY SHOWS DUAKLIR SIGNIFICANTLY IMPROVES LUNG FUNCTION IN MODERATE TO VERY SEVERE STABLE COPD